Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899337 | 0.78 | AKR1B1 (0.34) | MEN1KMT2AAKR1B1GAAHTT | |
| SCHEMBL3895767 | 0.78 | PNMT (0.42) | — | |
| SCHEMBL3903096 | 0.78 | CYP1A2 (0.49) | — | |
| SCHEMBL3898351 | 0.76 | LARS1 (0.39) | MAPT | |
| SCHEMBL3900013 | 0.70 | HDAC1 (0.44) | MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4617605 | 0.67 | AKR1B1 (0.48) | ADRA2AMEN1LMNACYP3A4HTR1A | |
| SCHEMBL3899691 | 0.65 | CA1 (0.41) | CYP3A4HTR2AHTR2CADRA1ADRD3 | |
| SCHEMBL3901130 | 0.65 | SLC1A3 (0.38) | — | |
| SCHEMBL2852938 | 0.63 | TAAR1 (0.56) | ADRA2AMEN1LMNACYP3A4HTR1A | |
| SCHEMBL29397997 | 0.63 | SLC7A5 (0.55) | MEN1CYP2C19KMT2AHSD17B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | claimed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | claimed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | disclosed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229341-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | ADRA2A 4490/4885MEN1 2495/4885LMNA 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.